tbuckley/cabot-search huggingface dataset:
Relapse of hepatocellular carcinoma (HCC) after liver transplantation (LT): A single-center analysis on 139 patients in the sorafinib era.
Authors: T. E. Pfiffer, D. Seehofer, A. Nicolaou, R. Neuhaus, H. Riess, P. Neuhaus, R. Trappe
Journal: Journal of Clinical Oncology (2010)

4088 Background: A growing number of patients (pts) with HCC are submitted to LT but data for treatment after recurrence under ongoing immunosuppression are still limited. Methods: We performed a univariate and multivariate, retrospective analysis on adult HCC pts consecutively referred to the Charité university hospital for LT between 01/2002 and 04/2009. Study endpoints were rate and risk factors of/for recurrence, overall survival after LT (OSLT) and OS after recurrence (OSR). Results: A total of 139 pts were included. The median follow up after LT was 37.2 months (m). 24/139 (17.3%) pts had recurrence. Independent RF for recurrence were macroscopic vascular invasion (OR = 6.7, [CI] 95% = 2.9-15.8; p < 0.001) and the presence of multiple tumor lesions (OR = 15.4, [CI] 95% = 3.8-61.8, p < 0.001). There was no recurrence in pts with Milan criteria (p < 0.001). 3-year OSLT was 53.5% for pts with recurrence versus 85.2% for pts without (p < 0.001). Mean OSR (mOSR) was 19.1 m ([CI] 95% = 13.1-25.2 m). 72.7% of pts had treatment of HCC after recurrence with a mean number of 2.2 treatment types per pt. mOSR for pts receiving treatment (23.6 m, [CI] 95%=17.0-30.3 m) was significantly higher than mOSR for pts on best supportive care (BSC; mOSR = 7.5 m, [CI] 95% = 2.6-12.4 m; HR = 6.8, [CI] 95% = 1.6-29.4, p = 0.010). However, only metastasectomy (which was possible in 31.8% of pts) significantly improved outcome by multivariate analysis (mOSR = 22.0, ([CI] 95%=13.2-30.7 m; HR=1.6, [CI] 95% = 1.2-19.8, p = 0.023) and there was a trend for a better outcome in pts that received radiotherapy in first to fourth-line (p = 0.094). Mean time to relapse after metastasectomy was 15.8 m. In 13.6% of pts that had multiple hepatic lesions at recurrence without evidence of extra-hepatic disease, ablation and/or hepatic-arterial chemotherapy resulted in a mOSR of 22.9 m, while sorafenib that was used in 36% of pts in 1st to 6th-line resulted in a mOS after start of treatment of 8.4 m. Conclusions: Treatment of relapsed HCC in pts on immunosuppression after LT prologs survival and especially metastasectomy is of major benefit. There is a trend for a better outcome in patients that had radiotherapy. The therapeutic effect of sorafenib is limited. No significant financial relationships to disclose.
Effect of Germline Polymorphisms on Clinical Outcome in Hodgkin’s Lymphoma (HL).
Authors: Anna Gaya, Alvaro Urbano-Ispizua, Alfons Navarro, Aina Pons, Pau Abrisqueta, Carmen Martinez, Miquel Granell, Antonio Martinez, Armando Lopez-Guillermo, Emili Montserrat, Mariano Monzo
Journal: Blood (2006)
Management trends in the United States for low-, intermediate-, and high-risk prostate cancer.
Authors: Kamran A. Ahmed, Jongphil Kim, Matthew C. Biagioli, Daniel Celestino Fernandez, Julio Pow-Sang, Michael Adam Poch, Richard Wilder
Journal: Journal of Clinical Oncology (2014)

5065 Background: The purpose of this study is to determine recent trends in the United States regarding management of clinically localized prostate cancer. Methods: A population-based analysis was conducted of 216,785 men with low (29%), intermediate (49%), or high (22%) recurrence risk prostate cancer, as defined by the National Comprehensive Cancer Network (NCCN). Annual rates of utilization of surgery, external beam radiation therapy, brachytherapy, external beam radiotherapy and brachytherapy, and no treatment between 2004 and 2010 were determined using the Surveillance, Epidemiology and End Results (SEER) database. Results: White patients were more likely than African American patients to undergo surgery (44.0% vs. 33.3%, respectively; p<.0001), and African American patients were more likely than White patients to undergo radiotherapy (28.1% vs. 22.6%, respectively; p<.0001) or no treatment (20.3% vs. 16.0%, respectively; p<.0001). There was an annual increase of 1.38% (95% confidence interval (CI) 1.06% to 1.70%) in surgery utilization corresponding to a 7.6% increase in utilization over the period of analysis. Using multivariate analysis, patients were more likely to receive no treatment if they were single (odds ratio (OR) 1.65; 95% CI 1.60-1.70), diagnosed in 2010 (vs. 2009 or earlier, OR = 1.18; 95% CI 1.14 -1.22), had low risk disease (vs. high risk, OR = 2.14; 95% CI 2.07-2.21), African American (vs. White, OR=1.42; 95% CI 1.37-1.47), resided in a county with a low education level (vs. high educational level, OR=1.30; 95% CI 1.26-1.35), or were >65 (vs. ≤ 65, OR = 2.25; 95% CI 2.19-2.31). For low risk prostate cancer, there was an annual decrease of 2.29% (95% CI -2.77% to -1.81%) in utilization of brachytherapy corresponding to a 14.3% decrease over the period of analysis and an annual increase of 2.57% (95% CI 1.79% to 3.36%) in patients receiving no treatment corresponding to a 15.7% increase. Conclusions: In patients with low risk prostate cancer, there was decreasing utilization of brachytherapy and increasing utilization of no treatment. Patients were less likely to receive treatment if they had low risk disease or were >65, African American, single, or resided in a county with a low educational level.
Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).
Authors: Sophie Dupire, Houria Debarri, Laurent Pascal, Valerie Coiteux, Benedicte Hivert, Christophe Willekens, Julien Rossignol, Ibrahim Yakoub-Agha, Brigitte Onraed, Jean-Luc Faucompré, Bernadette Hennache, Charles Dumontet, Thierry Facon, Xavier Leleu
Journal: Blood (2009)
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
Authors: Lee S. Schwartzberg, Denise A. Yardley, Anthony D. Elias, Manish Patel, Patricia LoRusso, Howard A. Burris, Ayca Gucalp, Amy C. Peterson, Martha E. Blaney, Joyce L. Steinberg, Jacqueline A. Gibbons, Tiffany A. Traina
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Several lines of evidence support targeting the androgen signaling pathway in breast cancer. Enzalutamide is a potent inhibitor of androgen receptor signaling. Preclinical data in estrogen-expressing breast cancer models demonstrated activity of enzalutamide monotherapy and enhanced activity when combined with various endocrine therapies (ET). Enzalutamide is a strong cytochrome P450 3A4 (CYP3A4) inducer, and ETs are commonly metabolized by CYP3A4. The pharmacokinetic (PK) interactions, safety, and tolerability of enzalutamide monotherapy and in combination with ETs were assessed in this phase I/Ib study. Experimental Design: Enzalutamide monotherapy was assessed in dose-escalation and dose-expansion cohorts of patients with advanced breast cancer. Additional cohorts examined effects of enzalutamide on anastrozole, exemestane, and fulvestrant PK in patients with estrogen receptor–positive/progesterone receptor–positive (ER+/PgR+) breast cancer. Results: Enzalutamide monotherapy (n = 29) or in combination with ETs (n = 70) was generally well tolerated. Enzalutamide PK in women was similar to prior data on PK in men with prostate cancer. Enzalutamide decreased plasma exposure to anastrozole by approximately 90% and exemestane by approximately 50%. Enzalutamide did not significantly affect fulvestrant PK. Exposure of exemestane 50 mg/day given with enzalutamide was similar to exemestane 25 mg/day alone. Conclusions: These results support a 160 mg/day enzalutamide dose in women with breast cancer. Enzalutamide can be given in combination with fulvestrant without dose modifications. Exemestane should be doubled from 25 mg/day to 50 mg/day when given in combination with enzalutamide; this combination is being investigated in a randomized phase II study in patients with ER+/PgR+ breast cancer. Clin Cancer Res; 23(15); 4046–54. ©2017 AACR.
Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State
Authors: John L. Magnani, Frans A Kuypers, John T. Patton, Sandra K Larkin, Lori Styles, Laura M DeCastro, Marilyn J. Telen, Ted Wun, Helen Thackray
Journal: Blood (2012)
Abstract A12: Contribution of the transcription factor STAT2 in the promotion and progression of colorectal cancer
Authors: Kevin P. Kotredes, Ana M. Gamero
Journal: Cancer Research (2017)

Abstract Accumulation of genetic lesions such as loss of, or mutations in the APC, KRAS, and TP53 genes play a pivotal role in the development and progression of colorectal cancer (CRC), the third most common cancer in the United States. Yet the effects deregulated signaling pathways, caused by these canonical alterations, may have on parallel signaling networks remain less clear. Signal Transducer and Activator of Transcription-2 (STAT2) is a critical molecule in the interferon transduction pathway, best known for its role in antiviral and antitumor immunity. However, we recently discovered that the transcription factor STAT2 functions as a promoter of colorectal carcinogenesis when tested in a model of colitis-associated CRC. In our recent study, we have reproduced this finding in which deletion of Stat2 in the ApcMin/+ mouse model of sporadic CRC also decreased the incidence and number of colon adenomas. We next investigated the role of STAT2 in the progression of CRC under the setting of p53 inactivation by employing isogenic colon carcinoma cells that differed in their p53 expression (p53+/+ vs. p53-/-). Our studies show that STAT2 knockdown weakened the oncogenic effects of p53 deficiency by drastically reducing migration and invasion whereas STAT2 knockdown had no effect in tumor cells with intact p53. In vivo, STAT2 depleted/p53-/- colon carcinoma cells, when transplanted in mice, formed smaller tumors when compared to tumor cells with intact STAT2 expression. Furthermore, we demonstrate expression of STAT2 dictates the expression of E-cadherin, a key epithelial-mesenchymal transition (EMT) marker, in the absence of p53. Additionally, evaluation of human CRC tissues revealed an increased STAT2 presence in the nucleus suggesting STAT2 is transcriptionally active in cancer; and genomic data mining of human CRC databases had led us to the identification of a putative STAT2 molecular signature upregulated in human CRC tumors. In conclusion, our study provides evidence that STAT2 has oncogenic properties thus positioning STAT2 as a major contributor to the pathophysiology of CRC. Citation Format: Kevin P. Kotredes, Ana M. Gamero. Contribution of the transcription factor STAT2 in the promotion and progression of colorectal cancer. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr A12.
High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic
Authors: Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, Sudhir Tauro, Gunes Gundem, Peter Van Loo, Andrea Pellagatti, Michael J Groves, Nick C.P. Cross, Carlo Gambacorti-Passerini, Anthony R Green, Jacqueline Boultwood, Paresh Vyas, Eva Hellstrom-Lindberg, David Bowen, Mario Cazzola, Michael R Stratton, Peter Campbell
Journal: Blood (2012)
Upregulation of Vav3 Is Required for Leukemogenesis By BCR-ABL through Polycomb Repression Complex Dependent De-Repression of the Cdkn2a Locus
Authors: Megha Desai, Kyung-Hee Chang, E. David Muench, Anjelika Gasilina, Ashley Wellendorf, Xose R Bustelo, H. Leighton Grimes, Nicolas Nassar, Jose A Cancelas
Journal: Blood (2015)
Characterization of Renal-Cell Carcinoma (RCC)-Reactive Cytotoxic T-Lymphocyte Responses Generated from Peripheral Blood of HLA-Matched Sibling and Unrelated Healthy Individuals in Vitro.
Authors: Mark Groene, Sandra Kausche, Elke Schnuerer, Volker Lennerz, Ralf G. Meyer, Thomas C. Wehler, Andreas Doerrschuck, Christoph Huber, Christine Falk, Wolfgang Herr
Journal: Blood (2004)
Systemic Activation of Platelet-Derived TGF-β1 Leads to Increased Smad2/3 Phosphorylation in Circulating Leukocytes and Platelet-Leukocyte Aggregates in a Mouse Model of Aortic Valve Stenosis
Authors: Wei Wang, Nathalie Burg, Spandana Vootukuri, Barry S. Coller
Journal: Blood (2014)
Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.
Authors: Anaadriana Zakarija, Hau C. Kwaan, Nicholas Banderanko, Dilip K. Pandey, John F. Cursio, Ivy M. Weiss, Thanh Ha Luu, Jeffrey L. Winters, Thomas L. Ortel, Thomas J. Raife, Ravindra Sarode, Charles L. Bennett
Journal: Blood (2007)
Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway
Authors: Ting-ting Wang, Yong-liang Zhao, Liu-sheng Peng, Na Chen, Weisan Chen, Yi-pin Lv, Fang-yuan Mao, Jin-yu Zhang, Ping Cheng, Yong-sheng Teng, Xiao-long Fu, Pei-wu Yu, Gang Guo, Ping Luo, Yuan Zhuang, Quan-ming Zou
Journal: Gut (2017)

<h3>Objective</h3> Neutrophils are prominent components of solid tumours and exhibit distinct phenotypes in different tumour microenvironments. However, the nature, regulation, function and clinical relevance of neutrophils in human gastric cancer (GC) are presently unknown. <h3>Design</h3> Flow cytometry analyses were performed to examine levels and phenotype of neutrophils in samples from 105 patients with GC. Kaplan-Meier plots for overall survival were performed using the log-rank test. Neutrophils and T cells were isolated, stimulated and/or cultured for in vitro and in vivo regulation and function assays. <h3>Results</h3> Patients with GC showed a significantly higher neutrophil infiltration in tumours. These tumour-infiltrating neutrophils showed an activated CD54<sup>+</sup> phenotype and expressed high level immunosuppressive molecule programmed death-ligand 1 (PD-L1). Neutrophils activated by tumours prolonged their lifespan and strongly expressed PD-L1 proteins with similar phenotype to their status in GC, and significant correlations were found between the levels of PD-L1 and CD54 on tumour-infiltrating neutrophils. Moreover, these PD-L1<sup>+</sup> neutrophils in tumours were associated with disease progression and reduced GC patient survival. Tumour-derived GM-CSF activated neutrophils and induced neutrophil PD-L1 expression via Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) signalling pathway. The activated PD-L1<sup>+</sup> neutrophils effectively suppressed normal T-cell immunity in vitro and contributed to the growth and progression of human GC in vivo; the effect could be reversed by blocking PD-L1 on these neutrophils. <h3>Conclusions</h3> Our results illuminate a novel mechanism of PD-L1 expression on tumour-activated neutrophils in GC, and also provide functional evidence for these novel GM-CSF-PD-L1 pathways to prevent, and to treat this immune tolerance feature of GC.
Differentiation of human and murine induced pluripotent stem cells to microglia-like cells
Authors: Hetal Pandya, Michael J Shen, David M Ichikawa, Andrea B Sedlock, Yong Choi, Kory R Johnson, Gloria Kim, Mason A Brown, Abdel G Elkahloun, Dragan Maric, Colin L Sweeney, Selamawit Gossa, Harry L Malech, Dorian B McGavern, John K Park
Journal: Nature Neuroscience (2017)
Abstract P1-10-10: Risk factors of locoregional recurrence, locoregional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes
Authors: S Wang, R Peng, J Jin, W Wang, Y Song, Y Liu, X Liu, Z Yu, H Fang, H Ren, Y Li
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Tale of Two Livers
Authors: Danielle Wallace
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bradycardia with Mitral Valve Prolapse
Authors: David Leichtman, Richard Nelson, Fredarick L. Gobel, Carl S. Alexander, Jay N. Cohn
Journal: Annals of Internal Medicine (2020)

Abstract Eleven members of a family with a high prevalence of mitral valve prolapse were investigated. Seven had documented sinus bradycardia, and five had mitral valve prolapse. Three patients wit...
Azacitidine Induces A Shift In Th1/Th17 Ratio and FoxP3 Expression In Anti-CD3 Stimulated CD4+ T-Cells; Implications for the Treatment of Myelodysplastic Syndromes
Authors: Hetty J Bontkes, Jurjen M Ruben, Theresia M. Westers, Gert J. Ossenkoppele, Arjan A. Van de Loosdrecht
Journal: Blood (2010)
Standing up for science in the era of Trump
Authors: Jose G Merino, Ashish Jha, Elizabeth Loder, Kamran Abbasi
Journal: BMJ (2017)

Be fair but challenging, critical but constructive





Any president of the United States is entitled to implement policies that reflect personal ideology and political beliefs. The public may disagree on the merits and drawbacks of these policies, but as long as the supporting arguments are based on facts and comply with constitutional principles then so be it. In its first weeks, however, Donald Trump’s presidency has raised worrying questions about its likely impact on science and health policy.1 2 Many of the new administration's pronouncements seem to place little value on facts or analysis. They also seem lacking in careful consideration of the consequences for biomedical research, healthcare, and ultimately the health of people in the US and the rest of the world.3

We are particularly concerned that Trump’s administration is acting in ways that will suppress research and limit communication on scientific topics that it deems politically inconvenient. All scientific communications from the Environmental Protection Agency may need to be approved by political appointees before being presented or published.2 Scientists from the Department …
Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).
Authors: Andreas Josting, Christian Rudolph, Markus Mapara, Jan-Peter Glossmann, Markus Sieber, Hartmut H. Kirchner, Bernd Dörken, Dieter K. Hossfeld, Jens Kisro, Bernd Metzner, Wolfgang E. Berdel, Volker Diehl, Andreas Engert
Journal: Blood (2004)
A Randomized Trial of Levamisole versus Placebo as Adjuvant Therapy in Malignant Melanoma
Authors: Lynn E. Spitler, Richard Sagebiel
Journal: New England Journal of Medicine (1980)

We conducted a randomized double-blind trial of levamisole versus placebo as adjuvant therapy for surgical treatment of melanoma. Of 203 patients entered into the study, 104 received levamisole and 99 placebo. The distribution of prognostic variables was similar in both groups, indicating the efficacy of the randomization and the absence of bias. Three end points were analyzed: disease-free interval, time to appearance of visceral metastasis, and survival. There was no statistically significant difference between the groups regarding any of these end points. In patients with Stage I disease, there was a trend in favor of levamisole regarding time to first visceral recurrence and survival (P = 0.07). We conclude that levamisole has no benefit, as compared with placebo, as adjuvant therapy for malignant melanoma. (N Engl J Med. 1980; 303: 1143–7.)
Longitudinal Strain as Risk Factor for Outcome in Pediatric Dilated Cardiomyopathy
Authors: S.L. den Boer, G.J. Sarvaas, L.M. Klitsie, G.G. van Iperen, R.B. Tanke, W.A. Helbing, A.P. Backx, L.A. Rammeloo, M. Dalinghaus, A.D. Ten Harkel
Journal: Journal of the American College of Cardiology (2016)
Extraneural Metastases From Desmoplastic Medulloblastoma Masquerading as Lymphoma
Authors: Abhishek Mahajan, Peter Paul, Epari Sridhar, Venkatesh Rangarajan, Tejpal Gupta, Girish Chinnaswamy, Aliasgar Moiyadi, Rakesh Jalali
Journal: Clinical Nuclear Medicine (2017)

Medulloblastoma is a WHO grade IV neoplasm that is usually restricted to the central nervous system, with metastasis occurring along the neuraxis through the ventricular system and cerebrospinal fluid. Extraneural metastasis is rare, usually occurs in bones/lymph nodes, and carries poor prognosis. We report multimodal imaging in a 14-year-old boy with desmoplastic medulloblastoma having multiple extraneural nodal and skeletal metastases, which was misdiagnosed as lymphoma. This case highlights the importance of understanding tumor biology with active clinical and radiological surveillance that is useful in early detection of extraneural metastasis of this aggressive tumor that helps in advocating appropriate and timely treatment.
The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.
Authors: Roger D. Yusen, Russell D. Hull, Sebastian M. Schellong, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie
Journal: Blood (2007)